Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Vaxcyte, Inc. (PCVX)
Company Research
Source: GlobeNewswire
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study Modified VAX-31 Infant Phase 2 Dose-Finding Study Advanced to Third and Final Stage Company Expects to Initiate VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with Topline Data in 2026 Company Establishing Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy, Aligned with Administration’s Focus on Strengthening Domestic Biomanufacturing and Representing up to $1 Billion in Manufacturing and Services Company Appoints Mike Mullette as Chief Commercial Officer as it Advances VAX-31 to Phase 3 and Potential Commercialization Company Remains Focused on Disciplined Capital Allocation and Prioritizing Resources for PCV Programs with Approximately $2.7 Billion in Cash, Cash Equivalents and Inve
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (NASDAQ:PCVX) was given a new $77.00 price target on by analysts at Leerink Partners.MarketBeat
- Medicxi Announces €500 Million Fund V [Yahoo! Finance]Yahoo! Finance
- Medicxi closes fifth fund to back ‘asset-centric' startups [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $85.00 price target on the stock.MarketBeat
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- PCVX's page on the SEC website